KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

This guideline replaces the ANCA chapter of the 2021 glomerular-diseases document. Rituximab and cyclophosphamide are put on an equal footing for remission induction, the reduced-dose glucocorticoid taper from PEXIVAS becomes the default, and plasma exchange is demoted to a case-by-case option for very severe kidney involvement or alveolar haemorrhage. Avacopan enters as a glucocorticoid-sparing alternative. Rituximab is preferred for maintenance, with duration guided by relapse risk. The register's trials are grouped by treatment principle below.

This guideline cites 3 of the 58 landmark trials in our Nephrology register.

Source

Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. Kidney Int. 2024;105(3S):S71–S116. · Kidney International

DOI

10.1016/j.kint.2023.10.008